Advicenne annual combined general meeting of June 8, 2023

Availability of preparatory documents

PARIS--(BUSINESS WIRE)--Regulatory News:

Advicenne (Euronext Growth Paris ALDVI - FR0013296746)(Paris:ALDVI), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering from rare renal diseases, informs its shareholders that it will hold its combined general meeting on June 8, 2023 at 10:00 am (CET), at 262, rue du Faubourg Saint-Honoré - 75008 Paris - France.

The preliminary notice, which includes the agenda and proposed resolutions, was published in the “BALO” (French journal of mandatory statutory notices) on May 1, 2023. The notice of meeting was published in the BALO and in a legal gazette on May 19, 2023.

The preparatory documents for the meeting set out in Article R. 22-10-23 of the French Commercial Code are available on the company's website (www.advicenne.com).

The preparatory documents for the meeting will also be made available to the shareholders as from the date of the meeting.

The full text of the documents to be presented at the meeting, in accordance with Articles L. 225-115 and R. 225-83 of the French Commercial Code, are available at the Company's registered office. Any shareholder may request that the Company transmit them the documents and information mentioned in Articles R. 225-81 and R. 225-83 of the French Commercial Code.

About Advicenne

Advicenne (Euronext: ALDVI) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product Sibnayal® (ADV7103) has received its Marketing Approval for distal renal tubular acidosis in EU and GB. ADV7103 is currently in late-stage development in cystinuria in Europe and in dRTA and cystinuria in the US and in Canada. Headquartered in Paris, Advicenne, listed on the Euronext Paris stock exchange since 2017, has now been listed on Euronext Growth Paris since its transfer on March 30, 2022. For additional information, see: https://advicenne.com/.

Disclaimer

This press release contains certain forward-looking statements concerning Advicenne group and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Advicenne considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the 2022 Universal Registration Document filed with the French financial market authority on April 28, 2023 (a copy of which is available on www.advicenne.com) and to the development of economic conditions, financial markets and the markets in which Advicenne operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Advicenne or not currently considered material by Advicenne. The occurrence of all or part of such risks could cause actual results, financial conditions, performance, or achievements of Advicenne to be materially different from such forward-looking statements. Advicenne expressly declines any obligation to update such forward-looking statements.